Charlotte Pahl
Directeur/Membre du Conseil chez Reponex Pharmaceuticals A/S
Fortune : 157 152 $ au 30/06/2024
Postes actifs de Charlotte Pahl
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
Reponex Pharmaceuticals A/S
 Reponex Pharmaceuticals A/S BiotechnologyHealth Technology Part of Pharma Equity Group A/S, Reponex Pharmaceuticals A/S operates as a Danish clinical stage biopharmaceutical company. The company is based in Hørsholm, Denmark. The company was founded in 2006. The CEO is Soren Nielsen. Reponex Pharmaceuticals was acquired by Pharma Equity Group A/S on March 24, 2023 for $109.83 million. | Directeur/Membre du Conseil | - | - |
Historique de carrière de Charlotte Pahl
Statistiques
Internationale
| Danemark | 2 |
Opérationnelle
| Director/Board Member | 1 |
Sectorielle
| Health Technology | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Entreprise privées | 1 |
|---|---|
Reponex Pharmaceuticals A/S
Reponex Pharmaceuticals A/S BiotechnologyHealth Technology Part of Pharma Equity Group A/S, Reponex Pharmaceuticals A/S operates as a Danish clinical stage biopharmaceutical company. The company is based in Hørsholm, Denmark. The company was founded in 2006. The CEO is Soren Nielsen. Reponex Pharmaceuticals was acquired by Pharma Equity Group A/S on March 24, 2023 for $109.83 million. | Health Technology |
- Bourse
- Insiders
- Charlotte Pahl
- Expérience
